Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma

T. Kewalramani, Stephen D Nimer, A. D. Zelenetz, S. Malhotra, J. Qin, J. Yahalom, Craig Moskowitz

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

To determine the outcome of patients with chemosensitive relapsed or primary refractory Hodgkin's disease (HD) or aggressive non-Hodgkin's lymphoma (NHL) whose disease progresses after autologous stem cell transplantation (ASCT), we reviewed the records of 82 patients with HD and 139 patients with NHL transplanted between 1993 and 2000. Disease progression occurred in 25 patients with HD and 66 patients with NHL, with median times to progression (TTP) of 3.8 and 5.1 months, respectively. Median survival times following ASCT failure were 26 and 7.7 months for patients with HD and NHL, respectively. The second-line international prognostic index (sIPI) and the TTP (before or after 3 months from ASCT) independently were predictive of survival for NHL patients. In addition, treatment with rituximab for patients with B cell NHL was associated with improved survival (median 28.6 vs 4.1 months, P=0.003), independent of the sIPI and TTP. Prognostic factors for patients with HD were not identified. Only two patients, one of whom was among six patients who received second autologous transplants, remain disease-free. The uniformly poor outcome associated with disease progression after ASCT should prompt efforts to assess the feasibility and utility of detecting and treating post transplant residual disease during a minimal disease state, before overt progression.

Original languageEnglish
Pages (from-to)673-679
Number of pages7
JournalBone Marrow Transplantation
Volume32
Issue number7
DOIs
StatePublished - Oct 1 2003
Externally publishedYes

Fingerprint

Autologous Transplantation
Hodgkin Disease
Non-Hodgkin's Lymphoma
Stem Cell Transplantation
Survival
Disease Progression
Autografts
B-Cell Lymphoma
Transplants

Keywords

  • Autologous transplantation
  • Hodgkin's disease
  • Non-Hodgkin's lymphoma
  • Progressive disease

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. / Kewalramani, T.; Nimer, Stephen D; Zelenetz, A. D.; Malhotra, S.; Qin, J.; Yahalom, J.; Moskowitz, Craig.

In: Bone Marrow Transplantation, Vol. 32, No. 7, 01.10.2003, p. 673-679.

Research output: Contribution to journalArticle

@article{312100a8d6144398b70c11d013213602,
title = "Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma",
abstract = "To determine the outcome of patients with chemosensitive relapsed or primary refractory Hodgkin's disease (HD) or aggressive non-Hodgkin's lymphoma (NHL) whose disease progresses after autologous stem cell transplantation (ASCT), we reviewed the records of 82 patients with HD and 139 patients with NHL transplanted between 1993 and 2000. Disease progression occurred in 25 patients with HD and 66 patients with NHL, with median times to progression (TTP) of 3.8 and 5.1 months, respectively. Median survival times following ASCT failure were 26 and 7.7 months for patients with HD and NHL, respectively. The second-line international prognostic index (sIPI) and the TTP (before or after 3 months from ASCT) independently were predictive of survival for NHL patients. In addition, treatment with rituximab for patients with B cell NHL was associated with improved survival (median 28.6 vs 4.1 months, P=0.003), independent of the sIPI and TTP. Prognostic factors for patients with HD were not identified. Only two patients, one of whom was among six patients who received second autologous transplants, remain disease-free. The uniformly poor outcome associated with disease progression after ASCT should prompt efforts to assess the feasibility and utility of detecting and treating post transplant residual disease during a minimal disease state, before overt progression.",
keywords = "Autologous transplantation, Hodgkin's disease, Non-Hodgkin's lymphoma, Progressive disease",
author = "T. Kewalramani and Nimer, {Stephen D} and Zelenetz, {A. D.} and S. Malhotra and J. Qin and J. Yahalom and Craig Moskowitz",
year = "2003",
month = "10",
day = "1",
doi = "10.1038/sj.bmt.1704214",
language = "English",
volume = "32",
pages = "673--679",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma

AU - Kewalramani, T.

AU - Nimer, Stephen D

AU - Zelenetz, A. D.

AU - Malhotra, S.

AU - Qin, J.

AU - Yahalom, J.

AU - Moskowitz, Craig

PY - 2003/10/1

Y1 - 2003/10/1

N2 - To determine the outcome of patients with chemosensitive relapsed or primary refractory Hodgkin's disease (HD) or aggressive non-Hodgkin's lymphoma (NHL) whose disease progresses after autologous stem cell transplantation (ASCT), we reviewed the records of 82 patients with HD and 139 patients with NHL transplanted between 1993 and 2000. Disease progression occurred in 25 patients with HD and 66 patients with NHL, with median times to progression (TTP) of 3.8 and 5.1 months, respectively. Median survival times following ASCT failure were 26 and 7.7 months for patients with HD and NHL, respectively. The second-line international prognostic index (sIPI) and the TTP (before or after 3 months from ASCT) independently were predictive of survival for NHL patients. In addition, treatment with rituximab for patients with B cell NHL was associated with improved survival (median 28.6 vs 4.1 months, P=0.003), independent of the sIPI and TTP. Prognostic factors for patients with HD were not identified. Only two patients, one of whom was among six patients who received second autologous transplants, remain disease-free. The uniformly poor outcome associated with disease progression after ASCT should prompt efforts to assess the feasibility and utility of detecting and treating post transplant residual disease during a minimal disease state, before overt progression.

AB - To determine the outcome of patients with chemosensitive relapsed or primary refractory Hodgkin's disease (HD) or aggressive non-Hodgkin's lymphoma (NHL) whose disease progresses after autologous stem cell transplantation (ASCT), we reviewed the records of 82 patients with HD and 139 patients with NHL transplanted between 1993 and 2000. Disease progression occurred in 25 patients with HD and 66 patients with NHL, with median times to progression (TTP) of 3.8 and 5.1 months, respectively. Median survival times following ASCT failure were 26 and 7.7 months for patients with HD and NHL, respectively. The second-line international prognostic index (sIPI) and the TTP (before or after 3 months from ASCT) independently were predictive of survival for NHL patients. In addition, treatment with rituximab for patients with B cell NHL was associated with improved survival (median 28.6 vs 4.1 months, P=0.003), independent of the sIPI and TTP. Prognostic factors for patients with HD were not identified. Only two patients, one of whom was among six patients who received second autologous transplants, remain disease-free. The uniformly poor outcome associated with disease progression after ASCT should prompt efforts to assess the feasibility and utility of detecting and treating post transplant residual disease during a minimal disease state, before overt progression.

KW - Autologous transplantation

KW - Hodgkin's disease

KW - Non-Hodgkin's lymphoma

KW - Progressive disease

UR - http://www.scopus.com/inward/record.url?scp=0141927874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141927874&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704214

DO - 10.1038/sj.bmt.1704214

M3 - Article

C2 - 13130314

AN - SCOPUS:0141927874

VL - 32

SP - 673

EP - 679

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 7

ER -